| Literature DB >> 23844295 |
Cattleya Thongrong1, Pornthep Kasemsiri, Ricardo L Carrau, Sergio D Bergese.
Abstract
Hemostasis is critical for adequate anatomical visualization during endoscopic endonasal skull base surgery. Reduction of intraoperative bleeding should be considered during the treatment planning and continued throughout the perioperative period. Preoperative preparations include the optimization of comorbidities and cessation of drugs that may inhibit coagulation. Intraoperative considerations comprise anesthetic and surgical aspects. Controlled hypotension is the main anesthetic technique to reduce bleeding; however, there is controversy regarding its effectiveness; what the appropriate mean arterial pressure is and how to maintain it. In extradural cases, we advocate a mean arterial pressure of 65-70 mm Hg to reduce bleeding while preventing ischemic complications. For dealing intradural lesion, controlled hypotension should be cautious. We do not advocate a marked blood pressure reduction, as this often affects the perfusion of neural structures. Further reduction could lead to stroke or loss of cranial nerve function. From the surgical perspective, there are novel technologies and techniques that reduce bleeding, thus, improving the visualization of the surgical field.Entities:
Year: 2013 PMID: 23844295 PMCID: PMC3697291 DOI: 10.1155/2013/191543
Source DB: PubMed Journal: ISRN Surg ISSN: 2090-5785
Various causes of bleeding tendency.
| Components | Causes |
|---|---|
| Vascular | Inherited Disorder |
| (i) Hereditary hemorrhagic telangiectasia | |
| (ii) Ehlers-Danlos syndrome | |
| Autoimmune disorder | |
| Allergic purpura | |
| Reduce the integrity of the blood vessel wall | |
| (i) Advanced age | |
| (ii) Prolonged steroid use | |
| (iii) Vitamin C deficiency | |
|
| |
| Platelets | Chronic diseases |
| (i) Kidney failure | |
| (ii) Liver disease: hepatitis, cirrhosis, and liver failure | |
| (iii) Splenic sequestration | |
| (iv) Hematologic malignancy: leukemia, lymphoma, and multiple myeloma | |
| (v) Bone marrow diseases | |
| (vi) Human immunodeficiency virus/acquired immunodeficiency syndrome | |
| (vii) Rare autosomal recessive disorders (Glanzmann's thrombasthenia and Bernard-Soulier syndrome) | |
| Autoimmune diseases | |
| (i) Idiopathic thrombocytopenic purpura | |
| (ii) Systemic lupus erythematosus | |
| Medications | |
| (i) Antiplatelet: aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) | |
| (ii) Antibiotic including penicillin, quinine, and sulfa | |
| Dietary supplements | |
| Vitamin E, fish oil, | |
|
| |
| Coagulation factors | Inherited disorder |
| (i) von Willebrand's disease | |
| (ii) Hemophilia | |
| (iii) Other inherited clotting factor deficiencies (factors II, V, VII, X, and XII) | |
| Medications | |
| (i) Warfarin (coumadin), heparin | |
| (ii) Chemotherapies | |
| (iii) Vitamin K deficiency | |
| Other disorders | |
| (i) Autoimmune disorders | |
| (ii) Disseminated intravascular coagulation (also results in thrombocytopenia) | |
| (iii) Liver disease | |
Comparison of clinical trials study between inhalation-and intravenous-based techniques in controlled hypotension during endoscopic endonasal surgery.
| Author (year) | Technique | Mean arterial pressure | Heart rate (beat/min) | Intraoperative bleeding | Surgical field score | Complication | Comment | |
|---|---|---|---|---|---|---|---|---|
|
Ankichetty et al. [ | Inhalation based: | Iso/Fen | Mean time to achieve target MAP: 18 ± 8 min | No significant difference | No significant difference |
No significant difference | No intra- and postoperative complications | No significant difference in sedation score, pain, nausea, vomiting, and hospital stay |
| Intravenous based: | Pro/Fen | Mean time to achieve target MAP: 16 ± 7 min | ||||||
|
| ||||||||
|
Yoo et al. [ | Inhalation based: | Sevo/Rem |
Initial: 91.1 ± 12.9 | 88.0 ± 21.8 | N/A | 2.21 (1–3) | N/A |
No significant differences of MAP ( |
| Des/Rem |
Initial: 92.2 ± 11.8 | 94.4 ± 20.0 | N/A | 2.07 (1–3) | N/A | |||
| Intravenous based: | Pro/Rem | Initial: 91.3 ± 11.3 | 79.1 ± 13.2 | N/A | 2.06 (1–3) | N/A | ||
|
| ||||||||
|
Ragab and Hassanin [ | Inhalation based: | Induction: Pro/Fen | Mean time to achieve target MAP: 3 ± 1.4 min | Decreased by | Mean 120 ± 43 mL | VAS 4.2 ± 1.4 | No serious adverse effects in both groups |
(i) Significant difference in time to achieve target MAP and decreased HR ( |
| Intravenous based: | Induction: Pro | Mean time to achieve target MAP: 4 ± 1 min | Decreased by | Mean 100 ± 39 mL | VAS 3 ± 1.2 | |||
|
| ||||||||
|
Ahn et al. [ | Inhalation based: | Sevo/Rem | N/A | N/A | 135 mL/h (in patient with high LM score) | Numeric rating scales: 5.8 ± 2.3 | N/A |
Significant better visualization in the high LM score patients in the intravenous based-group (blood loss |
| Intravenous based: | Pro/Rem | N/A | N/A | 19 mL/h | Numeric rating scales: 2.3 ± 1.0 | N/A | ||
|
| ||||||||
|
Beule et al. [ | Inhalation based: | Sevo/Fen | 70 ± 9.3 | 64.6 ± 6.6 | Mean | VAS 4.6 |
More impairment of platelet function in intravenous-based group ( |
No significant difference in all parameters ( |
| Intravenous based: | Pro/Fen | 71.5 ± 8.63 | 64.6 ± 7.3 | Mean 3.8 ± 1.6 mL/min | VAS 4.9 | |||
|
| ||||||||
|
Wormald et al. [ |
|
|
|
|
|
|
|
No significant differences in HR ( |
| Intravenous based: | Pro/Rem | 67.43 ± 1.62 | 62.34 ± 1.69 | N/A | 2.21 ± 0.11 | N/A | ||
|
| ||||||||
|
Sivaci et al. [ | Inhalation based: | Induction: Pro | Initial: 83 ± 5.7 | 76 ± 5.3 | Mean | N/A | N/A |
(i) Significant lower blood loss in intravenous-based group ( |
| Intravenous based: | Induction: Pro | Initial: 81 ± 3.7 | 65 ± 3.7 | Mean | N/A | N/A | ||
|
| ||||||||
|
Eberhart et al. [ | Inhalation based: | Iso/Alf | 67 (63–72) mmHg | 72 (66–83) | Estimated blood loss | VAS 4.9 | N/A | Significant decreased HR and better visualization in the intravenous based group ( |
| Intravenous based: | Pro/Rem | 65 (61–69) mmHg | 55 (51–64) | Estimated blood loss | VAS 2.8 | N/A | ||
Values are presented as mean ± SD or mean/medians (range); Iso: isoflurane; Sevo: sevoflurane; Des: desflurane; Pro: propofol; Fen: fentanyl; Rem: remifentanil; Esm: esmolol; Alf: alfentanil; VAS: visual analogue score; MAP: mean arterial pressure; HR: heart rate; LM: Lund-Mackay score; N/A: not available; P: Pvalue.
Review of controlled hypotension series in endoscopic endonasal surgery.
| Author (Year) | Target mean arterial pressure | Grading quality of surgical field | Blood loss | Comment | |
|---|---|---|---|---|---|
|
Boezaart et al. [ |
>65 mmHg | In SNP group* | In Esm group* | N/A | The optimum surgical conditions were provided with minimum Esm-induced hypotension (MAP > 65 mmHg); conversely, SNP induced hypotension (MAP 50–54 mmHg) |
|
| |||||
|
Jacobi et al. [ | Moderate controlled hypotension with SNP (65–75 mmHg) | 2.38 ± 0.77§ | 278 ± 110 mL |
(i) Total blood loss and grading quality of surgical field did not show significant difference between the groups | |
| Normotensive situation | 2.25 ± 0.63§
| 245 ± 132 mL | |||
|
| |||||
|
Mengistu et al. [ | Controlled hypotension group 50–55 mmHg | N/A | In Esm group 549 ± 208 mL | Blood loss shows significant difference between the controlled hypotension group and controlled group | |
| Controlled group 70–80 mmHg | N/A | 883 ± 465 mL | |||
*Using quality scale is proposed by Fromme et al. [35]; §Using numeric rating scale.
SNP: sodium nitropusside; Esm: esmolol; MAP: mean arterial pressure.
Controlled bleeding techniques in endoscopic endonasal surgery.
| Situation | Source | Technique |
|---|---|---|
| Artery | ||
| Low-flow bleeding |
Small perforating vessels | Bipolar electrocautery |
| Hemostatic biomaterial agents | ||
| High-flow bleeding | Medium to large artery | Bipolar electrocautery |
| Clips | ||
| Angiography embolization | ||
|
| ||
| Venous | ||
| Low-flow bleeding | Bleeding from mucosa, bone | Warm saline irrigation |
| Focal bleeding from venous sinus | Hemostatic biomaterial agents | |
| High-flow bleeding | Venous sinus bleeding | Hemostatic biomaterial agents |